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Objectives: Polypharmacy (use of ≥ 5 medications) increases the risk of drug-drug interactions and 
can lead to negative health outcomes. This study aimed to review the medications of people living 
with HIV (PLWH) and HIV negative controls in the POPPY study and evaluate the frequency of 
polypharmacy and potential drug-drug interactions (PDDI). 
Methods: Potential drug-drug interactions between non-antiretroviral (ARV) drugs were analysed 
using the Lexicomp® database, and PDDI between non-ARV and ARV drugs using the Liverpool drug 
interaction database (www.hiv-druginteractions.org). Between-group differences were assessed 
using Chi-squared, Mann-Whitney U and Kruskal Wallis tests. 
Results: This analysis included 698 PLWH ≥50 years, 374 PLWH <50 years and 304 HIV-negative 
controls ≥50 years. The prevalence of polypharmacy was 65.8% in older PLWH, 48.1% in younger 
PLWH, and 13.2% in the HIV negative group. When ARVs were excluded 29.8% of older PLWH and 
14.2% of younger PLWH had polypharmacy. The prevalence of ≥1 PDDI involving non-ARV drugs was 
36.1%, 20.3% and 16.4% respectively in older PLWH, younger PLWH and HIV negative controls. In 
PLWH the prevalence of ≥1 PDDI involving ARV and non-ARV drugs was 57.3% in older PLWH and 
32.4% in younger PLWH. 
Conclusion: Polypharmacy and PDDI involving non-ARV/ARV drugs and non-ARV/non-ARV drugs were 
common among older PLWH, highlighting the need for increased awareness and additional research 





With the advancement of antiretroviral (ARV) therapy, people living with HIV (PLWH) are living 
longer.1 The clinical focus has increasingly shifted from the management of HIV related complications 
to managing comorbidities,2 polypharmacy, and drug-drug interactions that may arise from 
medication use. There are many descriptions of the term polypharmacy, but it has commonly been 
defined in the literature as the regular use of five or more medications.3,4 Polypharmacy among PLWH 
specifically has been identified as a clinical concern. 5,6 A correlation between the number of non-ARV 
drugs and adverse health outcomes has been demonstrated in both older PLWH and uninfected older 
individuals. 7 Although polypharmacy is often unavoidable in older patients, including PLWH, the 
potential negative consequences of multi-medication intake must be carefully considered.  These 
include decreased adherence to treatments 8, increased risk of hospitalisation, increased risk of 
adverse drug reactions or additive drug toxicities 9,10, 11,12, increased costs 13, pill burden 14 and 
increased risk of geriatric syndrome, which is a collection of conditions traditionally associated with 
older age, including falls, delirium, incontinence and decreased nutrition status. 15,16 A major concern 
about polypharmacy is the risk of clinically significant potential drug-drug interactions (PDDI).17,18   
PDDI are a well-recognised concern in PLWH19,20, 21as ARVs can be inhibitors (e.g. ritonavir, cobicistat), 
inducers (e.g. efavirenz, nevirapine) or substrates (e.g. rilpivirine, maraviroc and the newer agents 
bictegravir and doravirine) of the cytochrome P450 (CYP450) system isoenzymes. 22,23 Drugs may alter 
the function of enzymes (eg UDP glucuronosyltransferases (UGTs)), transporters (eg P-glycoprotein   
(P-gp), organic anion/cation transporters etc. Interactions involving ARVs may also occur with drugs 
that alter gastric pH (e.g proton pump inhibitors), and drugs that act as chelating agents (eg calcium 
and magnesium containing compounds) may affect ARV absorption.23,24 The consequences of such 
PDDI may be serious toxicities or a reduction in ARV drug concentrations that leads to virological 
failure and development of resistance to ARV therapy.25  
Although traditionally the focus has been on ARV/non-ARV PDDI, PDDI involving non-ARVs in PLWH 
are also of emerging concern, in view of the high levels of non-ARV polypharmacy encountered in this 
population. Our aim was to analyse the prevalence of PDDI between both ARV/non-ARVs and non-
ARVs/non-ARVs in three groups of people: PLWH ≥ 50 years of age, younger PLWH, and people without 







The Pharmacokinetic and Clinical Observations in People Over 50 (POPPY) study is a multicentre, 
prospective, observational study, with data collection taking place over a three-year period from 2013-
2016. 26 Data from 1376 participants were collected: PLWH ≥ 50 years (n = 698), PLWH 20-49 years (n 
= 374), and HIV negative individuals ≥ 50 years (n = 304). The study comprises a cohort that represents 
the overall clinic population i.e. did not over-represent those with more complex medical needs who 
either attended clinic more frequently or those who were more regular participants in research 
studies. Where possible, HIV-negative participants were selected from similar underlying populations. 
Participants were recruited across eight clinical centres in the UK and Ireland. Ethical, regulatory and 
informed consent, if indicated, was obtained from each study site. 
Polypharmacy assessment 
Information on medication usage was obtained at study entry by trained study staff; additional 
information on ARV usage among PLWH was obtained through linkage with the UK Collaborative HIV 
Cohort (UK CHIC) study.27  Analyses were performed on data obtained at the baseline visit. For the 
purpose of this analysis the following medications were included: ARVs, non-ARV prescribed drugs, 
over the counter medications, dietary and vitamin supplements and homeopathic medications 
(recreational drugs were not included in the analysis). For both ARV and non-ARV combinations, 
individual components were counted and analysed separately e.g. Co-codamol® was inputted as 
paracetamol and codeine. Certain combinations, whose individual components could not possibly be 
determined e.g. “Multivitamin” were counted as one medicine. Medications were recorded and 
classified based on the World Health Organization (WHO) Anatomical Therapeutic Chemical 
Classification (ATC) system. Certain medicines were reclassified for example aspirin was only included 
in the blood (anti-platelet) category of medications. Polypharmacy was defined as five or more 
medications in line with other published studies. 3,28,29 
Potential drug-drug interactions 
For PLWH, the University of Liverpool HIV drug interactions database (www.hiv-druginteractions.org) 
was used to determine interactions between ARV and non-ARV medications. The interaction checker 
classifies specific ARV and non-ARV combinations as being contraindicated (colour code red), 
potentially clinically significant that are likely to require additional monitoring, alteration of drug 
dosage or timing of administration (colour code amber) or having no interaction (colour code green).30 
The option to check interactions between ARVs was not used, as it was assumed these interactions 
were intentional e.g darunavir and ritonavir, where ritonavir is used a pharmacokinetic enhancer. 
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For both HIV positive and negative participants, the Lexicomp® database was used to check 
interactions between non-ARV/non-ARV medications. Lexicomp® classifies interactions as class A (no 
known interaction), B (no action needed), C (monitor therapy), D (consider therapy modification), and 
X (avoid combination). 31 Examples in class X include co-administration of opioids with other opioids 
or co-administration of domperidone with quinolones.  In this study the interactions categorised in 
class D were sub-divided into those requiring therapy modification and those that could be managed 
by separating administration times e.g levothyroxine and calcium.  All interactions were included, 
except interactions between two drugs that were duplicated due to different mechanisms of 
interaction e.g two drugs which may both lower seizure threshold and prolong QTc interval. These 
combinations were only included once with the highest severity assigned to the interaction.  
Statistical Analysis  
Proportions, frequencies, means and ranges were used for the descriptive analyses. Patient 
characteristics between groups were compared using Pearson’s chi-square tests for categorical 
variables and non-parametric Kruskal-Wallis tests for continuous variables. Multivariable logistic 
regression models were used to assess the association of PDDI between non-ARV and non-ARV drugs 
and PDDI between ARV and non-ARV drugs with HIV group after adjusting for gender and race and 
current combination antiretroviral therapy (cART). Statistical analysis was performed using Microsoft 




The characteristics of the study population are illustrated in Table 1. Reflecting the characteristics of 
the older HIV-positive population in the UK and Ireland, the older group of PLWH were 
predominantly male, men who have sex with men (MSM) and of white ethnicity; the younger group 











In PLWH ≥ 50 years ATC class C, the cardiovascular system, was the most common therapeutic class 
accounting for 19.7% (n=479) of the 2426 co-medications in this group. ATC class N, drugs used to 
treat the nervous system, accounted for 16.8% (n=408) of all co-medications. ATC Class J, anti-
infectives for systemic use, accounted for 10.8% (n=261) and ATC Class A, drugs for the Alimentary 
Tract and Metabolism made up 8.9% (n=215) of all co-medications.  
In PLWH < 50 years, ATC class N was the most common therapeutic class, accounting for 20.1% 
(n=146) of the 726 co-medications. ATC class J made up 10.2% (n=74) of all co-medications, and ATC 
Class R, respiratory medicines, accounted for 9.4% (n=68). 
In the HIV-negative group ≥ 50 years ATC class C was the most common therapeutic class, 
accounting for 17.9% (n=107) of the 598 co-medications. ATC Class N made up 8.5% (n=51) of all co-
medications and ATC Class A accounted for 7.9% (n=47). 
Non-Conventional Medications 
A large proportion of all three groups were taking non-conventional medications (e.g vitamins, 
minerals, herbal and homeopathic remedies, dietary supplements). Among PLWH ≥ 50 years 228 
(32.7%) were taking at least one non-conventional medication, compared to 91 (29.9%) of those in 
the HIV-negative group ≥ 50 years and 127 (34%) of PLWH < 50 years. 
Polypharmacy 
The numbers of people with polypharmacy in each of the three groups is illustrated in Table 2. 
In PLWH > 50 years the group were taking a median of six medications including ARVs (Interquartile 
Range (IQR) 4,9), PLWH < 50 years were taking a median of four medications including ARVs (IQR 
3,6) and the HIV-negative group > 50 years were taking a median of one medication (IQR 0,3) (p = 
0.001). 
PLWH > 50 years had more polypharmacy than the other two groups: 459/698 (65.8%) older PLWH 
had polypharmacy compared to 180/374 (48.1%) younger PLWH and 40/304 (13.2%) HIV-negative 
people > 50 years (p = 0.001). 
When ARVs were excluded from the analysis in the HIV positive groups, 208/698 (29.8%) of older 
PLWH had polypharmacy. This is considerably more than the HIV negative group > 50 years, of whom 
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13.2% had polypharmacy. In younger PLWH 53/374 (14.2%) had polypharmacy when ARVs were 
excluded. 
 
Potential drug-drug interactions  
Table 2 reports the frequency of PDDI in the studied population.  A significantly higher proportion of 
older PLWH had at least one PDDI involving both an ARV/non-ARV than younger PLWH, and a non-
ARV/non-ARV than younger PLWH and the HIV negative group > 50 years. 
Potential drug-drug interactions between non-antiretrovirals and antiretrovirals 
Of the 913 total PDDI between non-ARV and ARV medications identified in older PLWH, 25 were 
classed as contraindicated interactions and 888 were classed as potential interactions. Clopidogrel 
(n=11) proton pump inhibitors (n = 5) and inhaled corticosteroids (n = 4) were the most frequently 
observed contraindicated co-medications in this group.  Among younger PLWH, 201 total PDDI were 
measured with four being classed as contraindicated interactions and 197 classed as potential 
interactions. Three contraindicated interactions in this group involved inhaled corticosteroids and one 
involved clopidogrel. The ARV medications implicated in contraindicated interactions were all in the 
protease inhibitor class. White ethnicity and belonging to the PLWH aged ≥ 50 years group increased 
the odds of PDDI between ARV and non-ARV drugs compared to PLWH aged < 50 years (odds ratio 
(OR)=2.00, [95% confidence interval (CI) 1.26, 3.18], p = 0.003 and OR=2.65 [95% CI 2.02, 3.47], p < 
0.001 respectively after adjusting for gender and current ARV regimen). Moreover, the POPPY 
participants on a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) without a Protease Inhibitor 
(PI), any Integrase Inhibitor (II) without a PI/NNRTI and participants on other ARV regimens compared 
to those on PI-containing regimen were 47%, 54% and 90% less likely to have a PDDI between ARV 
and non-ARV drugs (OR=0.53, [95% CI 0.41, 0.69], p <0.001, OR=0.46, [95% CI 0.28, 0.73, p=0.001 and 
OR=0.10, [95% CI 0.04, 0.26], p <0.001 respectively) (Table 5). 
Potential drug-drug interactions between non-antiretrovirals and non-antiretrovirals 
The odds of PDDI between non-ARV and non-ARV drugs was more than 3 times higher in PLWH aged 
>50 years compared to HIV-negative controls after adjusting for gender and race (odds ratio 3.08 
[2.16, 4.42], p < 0.001) (Table 5). 
As seen in Table 4 older PLWH had more interactions that were classed as “Do not co-administer” than 
the younger PLWH or older HIV negative controls (2.6% (n=31) of all non-ARV drug interactions versus 





In this analysis of polypharmacy from the POPPY study, we showed that among PLWH ≥ 50 years, 
74.5% were receiving at least one co-medication (i.e. medication other than ARVs), compared to 62% 
of PLWH < 50 years. Furthermore, we showed that polypharmacy was more common among older 
PLWH than HIV negative controls or younger PLWH, and that they were more at risk of a PDDI: i) 
involving non-ARV/non-ARV drugs than HIV-negative controls, and ii) involving non-ARV/ARV drugs 
than younger PLWH. This shows the importance of considering co-medications when assessing 
appropriate ARV treatment choices for this group. While this has likely occurred because of the 
increasing age of PLWH and subsequently the increased prevalence of diseases of older age in this 
group, it must also be considered that older PLWH may attend more individual specialists to deal with 
co-morbidities. While this practice may make it difficult to rationalise patient’s medication regimens, 
it should not preclude attempts to do so.   
A large scale Irish study of older people over 50 years found that 19% of participants had 
polypharmacy32, the results from our own study show significantly higher rates of polypharmacy in 
PLWH. It is not surprising that all PLWH had significantly more polypharmacy rates compared to the 
HIV negative group. Most of the studied PLWH were on ARV therapy, 98.7% of older PLWH and 94.9% 
of younger PLWH. Most ARV therapy comprises of at least three medications, and these were counted 
separately for the purposes of this study. Consequently, many PLWH only need to have an additional 
two medications to meet the criteria for polypharmacy as we have defined it in this study. However 
when ARVs were excluded 29.8% of older PLWH had polypharmacy. This finding suggests older PLWH 
are more likely to have a greater medication burden, independent of their ARV therapy. The reasons 
for this are multifactorial and could include the higher frequency of multimorbidity which seems to 
occur earlier in life in PLWH 33 and the involvement of various healthcare providers that prescribe 
different medications. There also may be a reluctance on the part of prescribers to reduce medication 
that has been started by prescribers from other specialities.  
There was a relatively small number of overall contraindicated interactions (2.7% (n=25) in older PLWH 
and 2% (n=4) in younger PLWH) between ARV and non-ARV medications. In older PLWH 3.6% (25/698) 
of people had a contraindicated ARV/non-ARV combination, and in younger PLWH 1.1% (4/374) of the 
group had a contraindicated combination. This  is of a similar prevalence to that in the Swiss cohort 
study (2%) 19, and an Australian cohort study (3%)34 which suggests good awareness of contraindicated 
combinations. Clopidogrel, proton pump inhibitors and corticosteroids were implicated in the majority 
of contraindicated interactions between non-ARV and ARV drugs, and it is clear that extra care should 
be taken to avoid these medications being co-prescribed along with protease inhibitors.  
9 
 
Furthermore, our study identified many PDDI involving non-ARV/non-ARV medications. Although 
these interactions varied in terms of severity, it is important to underline that some of the interactions 
described may be associated with clinically significant events.  Due to the higher rates of 
comorbidities, PLWH may be more vulnerable than the general population to the effects of 
complications associated with PDDI such as treatment failure or drug toxicity. The high prevalence of 
PDDI outside the use of ARVs in ageing PLWH suggests the need for better integrated, multidisciplinary 
care with regular review of co-medications. 
Having identified the areas in which these interactions occur and the recommended actions that 
should be taken, pre-emptive measures can be put in place to minimise the risk of a person 
experiencing an adverse outcome as the result of a DDI. Many studies examining polypharmacy only 
examine conventional medications, and do not include herbal medications and supplements which 
may result in underestimating polypharmacy. This study has shown that non-conventional 
medications make up a significant proportion of all co-medications, in all three populations in the 
study, and by including non-conventional medications a more accurate description of polypharmacy 
was obtained.  
There were limitations associated with our study. One study limitation was the lack of data on dosing 
information on most medications. This means that some interactions may have been overestimated 
as the interaction may only apply where the medication is taken above a certain dose e.g. aspirin has 
a different interaction profile depending if it used as an anti-platelet or an analgesic. Furthermore, 
some medications may have been started and stopped at various time points over the course of the 
study, as the medication list was collected at study entry and not updated after this. The medication 
list obtained was a self-reported list. Prompts were given to participants to provide as accurate a list 
as possible, however it is possible that medication use may have been underreported, especially 
herbal and other non-conventional medications. Although many centres have excellent 
communication between healthcare professionals, and between primary and secondary care, the lack 
of access to a complete prescription list that can be accessed by all healthcare professionals remains 
a limitation. Lexicomp® was the only interaction checker used in this study for non-ARV interactions. 
It is a sensitive interaction checker, and many of the interactions flagged may not be clinically relevant 
in practice, especially those classified as no action needed. Pill burden was not determined as data on 
specific formulations was not specifically sought, and where combination product names were 
provided these medications were separated for the purposes of this study.  
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In conclusion, the findings from our study suggest that older PLWH are at higher risk for polypharmacy 
and PDDI than younger PLWH and older HIV negative people. Importantly, even independently of ARV 
therapy, polypharmacy and PDDI are more common in older PLWH than older HIV negative adults.  
The findings above emphasise how imperative it is to focus on polypharmacy and PDDI in older PLWH 
who are taking multiple medications. There is a big focus on rationalising medications in the older 
population 35  and PLWH should not be exempt from this process. Older PLWH may benefit from input 
from specialists in geriatrics and pharmacy to ensure that all medications are rationalised and 
deprescribed if appropriate. Polypharmacy and PDDI in the HIV population are likely to increase in 
importance as the age of this cohort continues to rise. Priorities for the future should include focus on 
non-ARV interactions in older people with HIV, and rationalising medication use to ensure appropriate 
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Table 1: Characteristics of the study population 
 PLWH aged ≥50 
years 
PLWH aged <50 
years 
HIV-negative 
controls aged ≥50 
years 









































































N (%) taking ARV 
medications 
689(98.7%) 355(94.9%) n/a 
N (%) taking NRTI 594 (85.1%) 334 (89.3%) n/a 
N (%) taking PI 302 (43.3%) 139 (37.2%) n/a 
N (%) taking II 101 (14.5%) 49 (13.1%) n/a 
IQR: Interquartile range, PLWH: People Living With HIV, n/a: Not Applicable NRTI: Nucleoside Reverse Transcriptase 













Table 2: Numbers of medications and interactions in the three groups 
 
PLWH aged ≥50 
years 
PLWH aged <50 
years 
HIV-negative 
controls aged ≥50 
years 
p-value 












ARV medications in 
HIV-positive groups) 
   0.001 
0  178(25.5%) 142 (38%) 122 (40.1%)  
1-4 312 (44.7%) 179 (47.9%) 142 (46.7%)  
5-9 155 (22.2%) 49 (13.1%) 35 (11.5%)  
≥10 53 (7.6%) 4 (1.1%) 5 (1.7%)  
Numbers of people with 
polypharmacy 








Numbers of people with 
polypharmacy 
(≥ 5 medications) 







PDDI between non-ARV 
drugs 


















PDDI between ARV and 
non-ARV drugs 




























Table 3: Non-ARV drugs involved in interactions with ARVs 
PLWH ≥50 
years 
Number of total 
ARV/non-ARV 
interactions (%) 


















concentrations. Atorvastatin should be 
started at 10 mg daily and maximum dose 









Increased lamivudine concentrations. Co-
administration of treatment doses of 
trimethoprim/sulfamethoxazole should be 
avoided. 
Opioids 69 (7.6) Etravirine and Morphine Potential increase in morphine exposure. 
Opioid toxicity should be monitored for. 
Anti-
depressants 
67 (7.3) Atazanavir and Sertraline Potential increased sertraline exposure. 




58 (6.4) Darunavir/Ritonavir and 
Clopidogrel 
Decrease in active metabolite of 
clopidogrel which leads to insufficient 



























                
Increased Etravarine exposure. Limited 
clinical date on effect of this. 
Anti-
depressants 
22 (10.9)  Darunavir/Ritonavir/Efavirenz 
and Citalopram 
Increased Citalopram exposure. 





17 (8.5)  
 
Efavirenz and Atorvastatin 
 
Decreased Atorvastatin exposure. 
Cholesterol should be monitored, and 
dose of Atorvastatin may need to be 
increased. 
Hypnotics 16 (8)  Darunavir/Ritonavir and 
Zolpidem 
Increased exposure to Zolpidem which 
may increase sedation. 
Opioids 15(7.5) Darunavir/Ritonavir and 
Buprenorphine          
Potential increase in exposure to 
metabolites of buprenorphine. Opioid 
toxicity should be monitored for. 
PLWH: People Living with HIV, ARV: Anti-retroviral 
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controls aged ≥50 
years 
Example of interaction in this 
class and Clinical Effect 31 
Total non-ARV 
non-ARV PDDI  






1(0.4%) 1 (0.7%) Domperidone and Ciprofloxacin. 






41(17.1%) 23 (16.9%) Simvastatin and Amlodipine. 
Amlodipine increases exposure 
to simvastatin. Doses of 







7 (2.9%) 2 (1.5%) Doxycycline and Calcium. The 
absorption of doxycycline may be 
impaired by concurrently 
administered calcium. 




142(59.2%) 78 (57.4%)  Zolpidem and Citalopram. 
Increased risk of psychomotor 
impairment when these are co-
administered.  
No Action 189 
(15.9%) 
49(20.4%) 32 (23.5%) Aspirin and Ascorbic Acid. 
Aspirin may decrease the serum 
concentration of Ascorbic Acid. 




Table 5: Association of PDDI between non-ARV and non-ARV drugs and PDDI between ARV and non-
ARV drugs with HIV group, gender, race and ARV therapy. 
 PDDI between non-ARV and 
non-ARV drugs 
PDDI between ARV and non-ARV 
drugs 
 OR (95% CI) p-value* OR (95% CI) p-value* 
HIV group     
HIV-negative Ref.  - - 
PLWH aged <50 years 1.37 (0.91, 2.06) 0.13 Ref.  
PLWH aged ≥50 years 3.08 (2.16, 4.42) <0.001 2.65 (2.02, 3.47) <0.001 
     
Gender     
Female Ref.  Ref.  
Male 0.82 (0.56, 1.20) 0.31 0.75 (0.47, 1.21) 0.24 
Race     
Black African Ref.  Ref.  
White 0.98 (0.65, 1.47) 0.92 2.00 (1.26, 3.18) 0.003 
Current cART     
Any PI -  Ref.  
Any NNRTI without a PI -  0.53 (0.41, 0.69) <0.001 
Any II without a PI/NNRTI -  0.46 (0.28, 0.73) 0.001 
Others -  0.10 (0.04, 0.26) <0.001 
*p-values obtained from multivariable logistic regression models. 
PDDI: Potential Drug-Drug Interaction, ARV: Anti-retroviral, HIV: Human Immunodeficiency Virus, PLWH: People Living With 
HIV, OR: Odds Ratio, CI: Confidence Interval PI: Protease Inhibitor, NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor, 
II: Integrase Inhibitor 
 
